Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CD3 heavy chain-only antibody
- Development stage
- Preclinical
- Lead developer
- Adimab
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
The anti-CD3 heavy chain-only antibody (anti-CD3 HCAb) is a preclinical-stage recombinant single-domain (VHH) antibody targeting the CD3ε subunit of the human T-cell receptor complex. Developed by Adimab, these humanized binders were discovered by combining llama immunization with a yeast-based HCAb presentation and discovery platform. They are designed as modular building blocks for T-cell-engaging (TCE) multispecific therapeutics, where the CD3-binding arm recruits T cells to eliminate tumor cells. Lacking a light chain, these HCAbs simplify the design and manufacturing of multispecific formats (such as bispecific antibodies or VHH-TCR fusions) while maintaining potent T-cell activation and tumor-killing efficacy with a favorable developability profile.
- Other names
- anti-CD3 HCAbanti-CD-3 HCAbanti-CD 3 HCAbanti-CD3 heavy chain-only antibodiesanti-CD-3 heavy chain-only antibodiesanti-CD 3 heavy chain-only antibodies
02
Targets
CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on anti-CD3 heavy chain-only antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CD3 heavy chain-only antibody.